
Cardinal
Health, (NYSE:CAH), is the leading
provider of respiratory products to health care providers in the United
States. Cardinal Health businesses develop, manufacture, package and
market products for patient care; develop drug-delivery technologies;
distribute pharmaceuticals, medical-surgical and laboratory supplies;
and offer consulting and other services that improve quality and efficiency
in health care. Headquartered in Dublin, Ohio, Cardinal Health employs
approximately 50,000 people on five continents and produces annual revenues
of more than $47 billion. Cardinal Health is ranked number 19 on the
current Fortune 500 list and was named one of “The World’s Best”companies
by Forbes magazine in 2002.

Sepracor
Inc. is widely recognized in the
respiratory care category as the makers of XOPENEX® (levalbuterol
HCl) inhalation solution for the treatment or prevention of bronchospasm
in patients 6 years of age and older with reversible obstructive airway
disease, such as asthma. Sepracor is a research-based pharmaceutical
company dedicated to treating and preventing human disease through the
discovery, development, and commercialization of innovative pharmaceutical
products that are directed toward serving unmet medical needs. Sepracor's
drug development program has yielded an extensive portfolio of pharmaceutical
compound candidates, including candidates for the treatment of respiratory,
urology, and central nervous system disorders. Sepracor’s corporate
headquarters are located in Marlborough, MA.

Masimo, (NASDAQ: MASI) develops innovative
monitoring technologies that significantly improve patient care-helping
solve “unsolvable” problems. In 1995, the company debuted
Measure-Through Motion and Low Perfusion pulse oximetry, known as Masimo
SET, and with it virtually eliminated false alarms and increased pulse
oximetry’s ability to detect life-threatening events. More than 100
independent and objective studies demonstrate Masimo SET provides the
most trustworthy SpO2 and pulse rate measurements even under the most
difficult clinical conditions, including patient motion and low
peripheral perfusion. In 2005, Masimo introduced Masimo Rainbow SET, a
breakthrough noninvasive blood constituent monitoring platform that can
measure many blood constituents that previously required invasive
procedures. Rainbow SET continuously and noninvasively measures total
hemoglobin (SpHbTM) and oxygen content (SpOCTM) (both pending FDA
clearance), carboxyhemoglobin (SpCO(r)), methemoglobin (SpMet(r)), and
PVITM, in addition to oxyhemoglobin (SpO2), perfusion index (PI) and
pulse rate, allowing early detection and treatment of potentially
life-threatening conditions. Founded in 1989, Masimo has the mission of
“Improving Patient Outcomes and Reducing Cost of Care by Taking
Noninvasive Monitoring to New Sites and Applications.” Additional
information about Masimo and its products may be found at www.masimo.com.

With the acquisition of Diagnostics Products Corporation and Bayer Diagnostics, Siemens Medical Solutions is the first full service diagnostics company. By leveraging the strengths of all three companies, Siemens Medical Solutions Diagnostics is in the unique position to improve operational and financial outcomes across the continuum of care.
Siemens Medical Solutions Diagnostics offers a broad portfolio of performance-driven diagnostic solutions that assist in the diagnosis, monitoring and management of disease.
Our products and services bring together the right balance of science, technology, and practicality across the healthcare continuum to empower medical professionals with the vital information they need to deliver better, more personalized healthcare to patients around the globe.
The depth and breadth of our diagnostic systems—immunoassay, clinical chemistry, automation, molecular, hematology, and point-of-care—combined with a robust menu and IT offering deliver integrated, customer-focused solutions designed to meet the needs of any size laboratory, today and tomorrow.

Boehringer
Ingelheim Pharmaceuticals, Inc.,
based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer
Ingelheim Corporation (Ridgefield, CT) and a member of the Boehringer
Ingelheim group of companies. The Boehringer Ingelheim group of companies
ranks among the 20 leading pharmaceutical corporations in the world.
Headquartered in Ingelheim, Germany, it operates globally with 156 affiliates
in 44 countries and a total of about 32,000 employees. Since it was
founded in 1885, the family-owned company has been committed to researching,
manufacturing and marketing novel products of high therapeutic value
for human and veterinary medicine. In 2002, Boehringer Ingelheim
posted net sales of $7.2 billion (7.6 billion euro) while spending about
one fifth of net sales in its largest business segment Prescription
Medicines on research and development.
Covidien, formerly Tyco Healthcare, is a global $10 billion manufacturer of leading medical devices and supplies, imaging products and pharmaceuticals. The Company employs more than 43,000 people worldwide and is dedicated to working with medical professionals to improve patient outcomes. Its portfolio of leading brands includes Nellcor, Puritan Bennett, Mallinckrodt, Autosuture, Kendall, Syneture and Valleylab.

Monaghan Medical Corporation is a global leader in the
manufacture and sale of aerosol drug delivery devices and asthma management
products as well as a supplier to major pharmaceutical companies involved
with respiratory medicine in the United States. The company’s
strength lies in its science based approach to developing cost efficient,
outcome based products for aerosolized drug delivery including the well-known
brand names AeroChamber Plus® Valved
Holding Chamber, AeroVent® Collapsible
Holding Chamber, AeroEclipse® Breath Actuated
Nebulizer, and TruZone™ Peak Flow Meter.
Detailed clinical and contact information can be found on the company's
website, www.monaghanmed.com.

Respirionics is a leading developer, manufacturer and
distributor of products and programs that serve the global sleep and
respiratory markets. Focusing on emerging market needs, the Company
is committed to providing solutions to help improve outcomes for patients,
clinicians and health care providers. Respironics markets its products
in 131 countries and employs over 4,600 associates worldwide. Further
information can be found on the Company’s Web site: www.respironics.com.

IKARIA™ (formerly known as INO Therapeutics) is a uniquely positioned, fully integrated pharmaceutical company. The company possesses strong scientific capabilities in both pharmaceuticals and drug delivery devices, such as our flagship product INOmax® (nitric oxide) for inhalation and the INOvent®. The focus of the company is upon attaining leadership in the in-patient critical care market, by bringing to our customers innovative products that meet the needs of the critical care patient and the professionals who care for them.

Maquet Critical
Care provides innovative Servo mechanical ventilator medical
technology, ventilation knowledge, and complete product services for
critical care and sub-acute care providers. Maquet provides educational
programs to achieve tangible, sustainable patient outcomes while contributing
to cost-effectiveness. Maquet Critical Care maintains a total focus
on ventilation, from R&D through sales and service. Maquet works
closely with their customers to provide total ventilation solutions.
This is based on a tradition of electromedical devices going back more
than 30 years.

VIASYS
Healthcare Inc. is a global market leader in health-care
technology, distinction that is built on a solid history of innovation,
superior product performance, and commitment to customer service. VIASYS
Healthcare Inc. comprises many well-established companies that are recognized
for market leadership in the areas of respiratory care, neurology, vascular
medicine, critical care and the medical and surgical product markets.

ResMed is a leading respiratory medical device manufacturer, specializing in products for the diagnosis and treatment of sleep disordered breathing (SDB). ResMed operates through direct offices in the United States and several other countries, and through a network of distributors in more than 60 other countries.
When ResMed was formed in 1989, its primary purpose was to produce a device for treating obstructive sleep apnea. Developed in 1981 by Professor Colin Sullivan and colleagues at the University of Sydney, nasal continuous positive airway pressure (CPAP) provided the first successful noninvasive treatment of OSA. Since 1989, ResMed has maintained its focus on SDB, which is gaining greater public and physician awareness. Operations have grown dramatically through the introduction of a number of highly innovative product lines.

Dräeger
Medical AG & Co. KG is one of the world’s leading
manufacturers of medical equipment, the largest division of Drägerwerk
AG (history dates back to 1889) and a 65:35 joint venture company between
Drägerwerk AG and Siemens AG. The Company offers products, services
and integrated CareArea™ Solutions throughout the patient care
process—Emergency Care, Perioperative Care, Critical Care, Perinatal
Care and Home Care. Dräger Medical provides innovative solutions
for acute patient care which are the result of a clear focus on core
competencies, a close dialog with customers, over a century of experience
in the market, and continuous investment in R&D. With U.S. headquarters
in Telford, Pennsylvania and world headquarters in Lübeck, Germany,
Dräger Medical employs nearly 6,000 people worldwide.

Discovery
Labs is a
biotechnology company developing its proprietary surfactant technology
as Surfactant Replacement Therapies (SRT) for respiratory diseases.
Discovery Lab's technology produces a precision-engineered surfactant
that is designed to closely mimic the essential properties of natural
human lung surfactant. Discovery Labs believes that through its technology,
pulmonary surfactants have the potential, for the first time, to address
respiratory diseases where there are few or no approved therapies available.
Discovery Lab's SRT pipeline is Surfaxin® for RDS and BPD in premature
infants, and Aerosurf™ for neonatal respiratory failures. SRT
technology is also being developed to address the various respiratory
conditions affecting pediatric, young adult, and adult patients suffering
from ARDs, ALI, and COPD. Discovery Labs is located
in Warrington , PA.

DEY, L.P. is a specialty pharmaceutical company focused
on the development, manufacturing and marketing of prescription drug
products for the treatment of respiratory diseases, respiratory-related
allergies, and emergency care medicine. DEY is best known as one of
the largest US manufacturers of sterile, unit-dose inhalation solution
products. DEY is located in Northern California’s Napa Valley
with a distribution facility and customer service in Allen, Texas.
DEY, L.P. is an affiliate of Merck
KGaA, Darmstadt, Germany.

GE Healthcare provides solutions for tailored therapy
that are helping shape a new age of patient care. Advance critical care
ventilation and monitoring integration in the Engstrom Carestation features
new breakthrough methods in ventilation monitoring with SpiroDynamiacs
and FRC INview. Other solutions include a noninvasive and highly flexible
approach to heliox therapy using the Aptaer Heliox Delivery System .
And the Centiva/5 Critical Care Ventilator combines a compact size with
high levels of performance. Headquartered in the United Kingdom, GE
Healthcare is a $17 billion unit of General Electric Company (NYSE:GE).
Worldwide, GE Healthcare
employs more than 46,000 people committed to serving healthcare professionals
and their patients in more than 100 countries.